Results 171 to 180 of about 104,823 (289)

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Pragmatic health technology appraisals of biosimilars: a pilot case study of bevacizumab in colorectal cancer for NICE. [PDF]

Cost Eff Resour Alloc
Stevenson MD, Mon-Yee M, Forsyth JE, Montazeri A, Saunders MP.   +4 more
europepmc   +1 more source

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

Cancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Nobuyuki Katakami, Akira Kisohara, Masafumi Yamaguchi, Hirotaka Kuroki, Masamichi Sugimoto, Hisao Ashimura, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Hematological toxicities in bevacizumab associated with ovarian cancer: A pharmacovigilance study using FDA adverse event reporting system database. [PDF]

Medicine (Baltimore)
Zhou X, Su L, Lin Y, Cheng Z, Du Z, Han B, Wang X.   +6 more
europepmc   +1 more source

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

, 2012
Angela M Carneiro,1,2 Luis S Mendonça,1 Manuel S Falcão,1,2 Sofia L Fonseca,1 Elisete M Brandão,1 Fernando M Falcão-Reis1,21Department of Ophthalmology of Hospital de São João, Porto ...
Falcão MS, Carneiro AM, Brandão EM, Mendonça LS, Fonseca SL, Falcão-Reis FM   +5 more
core  

Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan

Cancer Science, EarlyView.
OS (A–D) and PFS (E–H) in patients receiving (A/E) Atezo + CnP, (B/F) Atezo + PP, (C/G) Atezo + bev + CP, and (D/H) Atezo + CEa by age (≥ 70 years and < 70 years). aSaito R, et al. Presented at the 2024 American Society of Clinical Oncology Annual Meeting. Abstract 8092. Adapted with permission by the author.
Junichi Shimizu, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Kozo Yoshimori, Kazuhiko Shibata, Takeshi Tsuda, Masahiro Seike, Takahiro Ota, Koichi Samata, Yuki Kobayashi, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Bevacizumab induces apoptosis in glioblastoma cells by upregulating miR-4695-5p to inhibit PKMYT1. [PDF]

RNA Biol
Shen Y, Yang C, Wang H, Hu S, Hao Y, Geng Y, Huang S.   +6 more
europepmc   +1 more source

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

, 2009
Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis.
Jia Li, Muhammad Wasif Saif
core  

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-enhancer Formation. [PDF]

Cancer Res
Li W, Peng J, He J, Liao L, Kang D, Zhang W, Wang W, Wang R, Wang S, Liao Y, Yu L, Ou Q, Fang Y, Wu X, Ding P, Pan Z, Zhou C, Lin J.   +17 more
europepmc   +1 more source